Tocotrienols for Normalisation of Hepatic Echogenic Response in Nonalcoholic Fatty Liver: a Randomised Placebo-controlled Clinical Trial

Overview

Journal Nutr J

Publisher Biomed Central

Specialty Nutritional Sciences

Date 2013 Dec 31

PMID 24373555

Citations 32

Authors

Enrico Magosso

Mukhtar Alam Ansari

Yogheswaran Gopalan

Ibrahim Lutfi Shuaib

Jia-Woei Wong

Nurzalina Abdul Karim Khan

Mohamed Rizal Abu Bakar

Bee-Hong Ng

Kah-Hay Yuen

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the commonest liver disorders. Obesity, insulin resistance, lipid peroxidation and oxidative stress have been identified amongst the possible hits leading to the onset and progression of this disease. Nutritional evaluation of NAFLD patients showed a lower-than-recommended intake of vitamin E. Vitamin E is a family of 8 isoforms, 4 tocopherols and 4 tocotrienols. Alpha-tocopherol has been widely investigated in liver diseases, whereas no previous clinical trial has investigated tocotrienols for NAFLD. Aim of the study was to determine the effects of mixed tocotrienols, in normalising the hepatic echogenic response in hypercholesterolaemic patients with ultrasound-proven NAFLD.

Methods: Eighty-seven untreated hypercholesterolaemic adults with ultrasound-proven NAFLD were enrolled and randomised into control group (n = 44) and tocotrienols group (n = 43). The treatment, either mixed tocotrienols 200 mg twice daily or placebo, had a 1-year duration.Normalisation of hepatic echogenic response, being the trial primary aim, was used in sample size calculations. The data were assessed according to intention to treat principle as primary outcome. Per protocol analysis was also carried out as secondary outcome measurement.

Results: Thirty and 34 participants concluded the study in the tocotrienols and placebo group respectively. Alpha-tocopherol levels were within the normal range for all subjects. As primary outcome, the normalisation of hepatic echogenic response was significantly higher for the tocotrienols treated group compared to the placebo group in the intention to treat analysis (P = 0.039; 95% CI = 0.896-6.488). As secondary objective, the per protocol assessment also showed significant rate of remission (P = 0.014; 95% CI = 1.117-9.456). Worsening of NAFLD grade was recorded in two patients in the placebo group, but none in the group treated with tocotrienols. No adverse events were reported for both groups.

Conclusion: This is the first clinical trial that showed the hepatoprotective effects of mixed palm tocotrienols in hypercholesterolemic adults with NAFLD.

Citing Articles

Vitamin E and Non-alcoholic Fatty Liver Disease: Investigating the Evidence Through a Systematic Review.

Abera M, Suresh S, Malireddi A, Boddeti S, Noor K, Ansar M Cureus. 2024; 16(10):e72596.

PMID: 39610563 PMC: 11602675. DOI: 10.7759/cureus.72596.

Vitamin E for people with non-alcoholic fatty liver disease.

Wen H, Deng H, Yang L, Li L, Lin J, Zheng P Cochrane Database Syst Rev. 2024; 10:CD015033.

PMID: 39412049 PMC: 11481097. DOI: 10.1002/14651858.CD015033.pub2.

Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial.

Al-Baiaty F, Ishak S, Mohd Zaki F, Masra F, Abdul Aziz D, Wan Md Zin W BMC Pediatr. 2024; 24(1):529.

PMID: 39160468 PMC: 11334366. DOI: 10.1186/s12887-024-04993-8.

Anticancer Activity of Delta-Tocotrienol in Human Hepatocarcinoma: Involvement of Autophagy Induction.

Montagnani Marelli M, Macchi C, Ruscica M, Sartori P, Moretti R Cancers (Basel). 2024; 16(15).

PMID: 39123382 PMC: 11311296. DOI: 10.3390/cancers16152654.

Incidence and Outcomes of Postoperative Atrial Fibrillation after Coronary Artery Bypass Grafting of a Randomized Controlled Trial: A Blinded End-of-cycle Analysis.

Musa A, Dillon J, Taib M, Yunus A, Sanusi A, Nordin M Rev Cardiovasc Med. 2024; 23(4):122.

PMID: 39076222 PMC: 11273857. DOI: 10.31083/j.rcm2304122.

References

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

Rasool A, Rahman A, Yuen K, Wong A . Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E. Arch Pharm Res. 2008; 31(9):1212-7. DOI: 10.1007/s12272-001-1291-5. View

Farrell G, Wong V, Chitturi S . NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5):307-18. DOI: 10.1038/nrgastro.2013.34. View

Tominaga K, Kurata J, Chen Y, Fujimoto E, Miyagawa S, Abe I . Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci. 1995; 40(9):2002-9. DOI: 10.1007/BF02208670. View

Kuhad A, Chopra K . Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci. 2009; 84(9-10):296-301. DOI: 10.1016/j.lfs.2008.12.014. View

Day C . Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16(5):663-78. DOI: 10.1053/bega.2002.0333. View

Letteron P, Fromenty B, Terris B, Degott C, Pessayre D . Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 1996; 24(2):200-8. DOI: 10.1016/s0168-8278(96)80030-4. View

Schwenzer N, Springer F, Schraml C, Stefan N, Machann J, Schick F . Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009; 51(3):433-45. DOI: 10.1016/j.jhep.2009.05.023. View

Harrison S, Torgerson S, Hayashi P, Ward J, Schenker S . Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98(11):2485-90. DOI: 10.1111/j.1572-0241.2003.08699.x. View

10.

Mofrad P, Contos M, Haque M, Sargeant C, Fisher R, Luketic V . Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37(6):1286-92. DOI: 10.1053/jhep.2003.50229. View

11.

Kugelmas M, Hill D, Vivian B, Marsano L, McClain C . Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003; 38(2):413-9. DOI: 10.1053/jhep.2003.50316. View

12.

Saadeh S, Younossi Z, Remer E, Gramlich T, Ong J, Hurley M . The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3):745-50. DOI: 10.1053/gast.2002.35354. View

13.

Brunt E, Tiniakos D . Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010; 16(42):5286-96. PMC: 2980677. DOI: 10.3748/wjg.v16.i42.5286. View

14.

Patel V, Rink C, Gordillo G, Khanna S, Gnyawali U, Roy S . Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012; 142(3):513-9. PMC: 3278267. DOI: 10.3945/jn.111.151902. View

15.

Serbinova E, Kagan V, Han D, Packer L . Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991; 10(5):263-75. DOI: 10.1016/0891-5849(91)90033-y. View

16.

Muto C, Yachi R, Aoki Y, Koike T, Igarashi O, Kiyose C . Gamma-tocotrienol reduces the triacylglycerol level in rat primary hepatocytes through regulation of fatty acid metabolism. J Clin Biochem Nutr. 2013; 52(1):32-7. PMC: 3541416. DOI: 10.3164/jcbn.12-97. View

17.

Magosso E, Alam Ansari M, Gopalan Y, Abu Bakar M, Khan N, Wong J . Prevalence of non-alcoholic fatty liver in a hypercholesterolemic population of northwestern peninsular Malaysia. Southeast Asian J Trop Med Public Health. 2010; 41(4):936-42. View

18.

Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A . Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 2001; 15(10):1667-72. DOI: 10.1046/j.1365-2036.2001.01083.x. View

19.

Burdeos G, Nakagawa K, Watanabe A, Kimura F, Miyazawa T . γ-Tocotrienol attenuates triglyceride through effect on lipogenic gene expressions in mouse hepatocellular carcinoma Hepa 1-6. J Nutr Sci Vitaminol (Tokyo). 2013; 59(2):148-51. DOI: 10.3177/jnsv.59.148. View

20.

Fracanzani A, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E . Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008; 48(3):792-8. DOI: 10.1002/hep.22429. View